Cagrilintide
A long-acting amylin analogue given as a weekly injection to enhance feelings of fullness and reduce food intake.
Plain English
Patient-Friendly Explanation
Cagrilintide is a newer weight loss medication that works by mimicking a hormone called amylin, which is naturally released by your pancreas after meals to help you feel full. It is given as a once-weekly injection and is being studied both alone and in combination with other GLP-1 medications for enhanced weight loss effects.
Medical
Clinical Definition
Cagrilintide is a long-acting amylin analogue that acts on amylin receptors in the area postrema and nucleus tractus solitarius to enhance satiety and reduce food intake. It has a half-life of approximately 7–8 days, allowing once-weekly subcutaneous administration. In a Phase 2 trial, cagrilintide 4.5 mg produced 10.8% weight loss at 26 weeks, and the combination of cagrilintide with a GLP-1 receptor agonist demonstrated up to 17.1% weight loss in early trials.
Key Insight
Why It Matters
Amylin-based therapies offer an alternative mechanism to GLP-1 agonists with potentially synergistic effects when combined. At Accord Medical Clinic, we stay informed about emerging therapies like cagrilintide to help patients explore the full range of medical weight management options.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: August 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.